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Abstract
OBJECTIVE: To investigate the clinical effect of Qin-
gxue Dan (QXD) on obesity and metabolic biomark-
er related to obesity.
METHODS: A randomized, double blinded, place-
bo-controlled trial with a paralleled study design
was conducted. Twenty-six obese volunteers aged
between 30 and 60 with obesity and more than 2
metabolic risk factors were recruited at the depart-
ment of oriental rehabilitation medicine, Kyung-
hee university oriental medical hospital, Seoul, Ko-
rea. Subjects were randomly assigned to an inter-
vention (QXD) group or a placebo group, and treat-
ed with 900 mg/d of QXD or placebo medicine for
8 weeks. Primary endpoint was the change of body
mass index (BMI) at 8 week from baseline. Second-
ary outcomes included the change of body compo-
sition, abdominal fat mass measured with Dual en-
ergy X-ray absorptiometry (DXA), blood pressure,
lipid profiles and the homeostasis model assess-
ment for insulin resistance (HOMA-IR).
RESULTS: BMI was decreased in the QXD group sig-
nificantly. Total body fat, abdominal fat mass mea-
sured with DXA Region of Interest and waist circum-
ference (WC) showed a trend toward decreasing in
the QXD group, but fat free mass was decreased in
all groups. Triglyceride (TG) was decreased in QXD
group significantly, but WC, total cholesterol and
high-density lipoprotein cholesterol were in-
creased in both group. BP didn't change during the
study period. HOMA-IR is decreased in both groups
without group effect.
CONCLUSION: 8-weeks of oral administrations of
QXD (900 mg/d) reduces BMI, with a tendency of
lose of total body fat mass, especially abdominal
fat. It also significantly reduced serum TG level.
These results suggest QXD could be used to treat
obesity and metabolic risk factors. Further study is
needed to confirm our pilot findings.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Obesity, particularly visceral obesity is the most
common cause of insulin resistance, dyslipidemia and
long-term vascular complications.1,2 Although the cause
of the syndrome remains obscure, visceral obesity was
considered as central factor.3,4
Qingxue Dan (QXD) is a herbal formula consisting of
Radix of Scutellaria baicalensis Georgi, Rhizoma of
Coptis japonica Makino, Cortex of Phellodendron
amurense Ruprecht, Fructus of Gardenia jasminoides
Ellis, and Rhizoma of Rheum palmatum Linne. An
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anti-hyperlipidemic activity,5,6 anti-hypertensive activity,7
anti-inflammatory actions,8 and anti-atherogenic
effects9,10 of QXD have been proved so far. A previous
study showed therapeutic effects of QXD on mice
model of obesity and metabolic syndrome.11 In the
current study, we hypothesized that QXD will reduce
body fat and improve other metabolic biomarkers in a
clinical population of patients with obesity and
metabolic risk factors.
MATERIALS ANDMETHODS
Study design
This randomized, double-blind, placebo-controlled
clinical study was conducted at Kyung Hee University
Oriental Medical Hospital from June 2009 to October
2009.
All procedures were carried out according to Declara-
tion of Helsinki guidelines. The study protocol was ap-
proved by the Institutional Review Board consent form
of the Medical Research Institute, Kyung Hee Medical
Center, Seoul, Korea (komcirb 2009-09).
Subjects
Subjects aged 30-60 years with obesity [body mass in-
dex (BMI) ≥ 25] who had more than 2 metabolic risk
factors according to the criteria of the International Di-
abetes Federation (IDF) were recruited for this pilot
study (Table 1).
The exclusion criteria included eating disorder, smok-
ing, a potentially confounding medical condition (e.g.
liver disease, renal disease, heart disease, thyroid dis-
ease, anemia etc.), taking medications that might affect
body weight and metabolism within last 3 months
(oral contraceptives or hormonal medications etc.),
pregnancy or plan to pregnant, and breast feeding
woman who has weight changes during recent 3 months.
Subjects were recruited by newspaper and Internet ad-
vertisement. Participants had to give both verbal and
written information regarding the study. Signed in-
formed consent was obtained prior to entry.
Materials
QXD (Code number: HH333) was obtained from
Kyung Hee University Oriental Medical center (Seoul,
Korea). QXD is a capsulated extract (300 mg per one
capsule) of Scutellariae Radix, Coptidis Rhizoma, Phello-
dendri Cortex, Gardeniae Fructus and Rhei Rhizoma (Ta-
ble 2). Each herbal medicine was extracted with 80%
ethanol in boiling water for 2 h. These extracts were fil-
tered and evaporated in a rotary vacuum evaporator
and then finally lyophilized with a freezing dryer. To
standardize the quality of QXD, berberine in Coptidis
Rhizoma and Phellodendri Cortex, baicalin in Scutel-
lariae Radix were quantitatively measured with high
performance liquid chromatography (HPLC) as an in-
dex component (Figure 1).12
The placebo capsules were made with phenylthiocarbo-
mide (PTC), squid ink, herbal flavor and starch, hav-
ing similar organoleptic properties including weight,
taste, color, odor and feel.
Randomization and treatment
Subject was randomly assigned to the treatment group
or placebo group using a computer random number
generator with SAS 9.2 software. The clinical trial phar-
Item
Abdominal Obesity (Waist circumference)
HDL-cholesterol
Risk factors
Men
Women
Triglyceride
Men
Women
Blood pressure
Fasting blood glucose
Defining level
>90 cm or ethnicity specific
>80 cm or ethnicity specific
≥150 mg/dL (1.7 mmol/L)
<40 mg/dL (1.03 mmol/L)
<50 mg/dL (1.29 mmol/L)
≥130/85 mm Hg
≥100 mg/dL (5.6 mmol/L)
Notes: IDF: international diabetes federation; HDL: high density lipoprotein.
Table 1 IDF Criteria for metabolic syndrome (central obesity + 2 criteria)
Table 2 Composition of QXD
Constitute herb
Scutellariae Radix
Coptidis Rhizoma
Phellodendri Cortex
Gardeniae Fructus
Rhei Rhizoma
Total
Scientific name
Scutellaria baicalensis GEORGI (from Korea)
Coptis japonica MAKINO (from Korea)
Phellodendron Amurense RUPRECHT (from Korea)
Gardenia jasminoides ELLIS (from korea)
Rheum palmatum L. (from korea)
Weight (g)
0.28
0.28
0.28
0.28
0.07
1.2
292
ChungW et al. / Clinical Study
JTCM |www. journaltcm. com June 15, 2016 |Volume 36 | Issue 3 |
macist and statistician secured the randomization codes
confidential.
The subjects in QXD group received 900 mg/d of en-
capsulated QXD extract, whereas the subjects in the
placebo group received 900 mg/d of encapsulated pla-
cebo for 8 weeks. Subjects visited the hospital once a
week and received QXD and placebo, and checked
blood pressure (BP), bioelectrical impedance analysis
for body composition (BIA), anthropometry and moni-
tored for adverse events. During the study periods, all
subjects had abstained from using alcohol and tobacco,
and had to write a self-reporting diet and exercise diary
everyday so that the investigators could monitor their
daily calorie intakes and outputs.
Outcome measurements
Primary endpoint was the change of BMI at 8 week
from baseline. Secondary outcomes included the
change of total body fat (TBF), fat free mass (FFM),
abdominal fat mass measured with the Dual energy
X-ray absorptiometry (DXA), BP, lipid profiles and the
homeostasis model assessment for insulin resistance
(HOMA-IR).
Each subject filled a questionnaire, providing details re-
garding demographics, medical history and nutritional
status at the baseline evaluation. In every visit, BP was
measured with a mercury sphygmomanometer (Hico,
Japan) in the seating posture after 10 min of rest.
Height was measured to the nearest 0.5 cm respectively
with wearing a hospital gown. Waist circumference
(WC) and hip circumference (HC) were measured by
the same observer twice according to the World Health
Organization method, at mid-point between the lower
end of the rib cage and top of the iliac crest in a stand-
ing position, which is usually 3 cm above the anterior
superior iliac spine.13 HC was measured at the level of
greater trochanter of femur. Body weights, body fat
mass (BFM) and FFM were measured to the nearest
0.1 kg with BIA (InBody 4.0, Biospace, Korea) at each
visit. TBF and FFM were measured with DXA scans
using Lunar iDXA enCORE 2007 Version 11.40 (Lu-
nar Radiation Corp., Madison,WI, USA) at baseline and
week 9. Specific DXA Region of Interest (ROI) for ab-
dominal regional fat was defined as from the upper edge
of the second lumbar vertebra to above the iliac crest. 14
Statistical analysis
The statistical analyses were performed using SPSS
18.0 for windows program (SPSS Inc., Chicago, IL,
USA). All analyses were performed on a per-protocol
basis. Significance was defined as P < 0.05, and all anal-
yses were two-tailed. Data are presented as means ±
standard deviation.
Baseline demographic data were compared between
two groups with Student's t-test or Fisher's exact test
for compatibility analysis. Efficacy analyses of out-
comes were performed with Student's t-test. Repeat-
ed measured data such as BP were analyzed with re-
peated measure analysis of variance, and safety analy-
sis for adverse event was analyzed with Fisher's exact
test.
RESULTS
Demographic characteristics of subjects
Thirty-one participants recruited in the screening pro-
cedures, and 5 were disqualified due to failure to fulfill
including criteria. A total of 26 subjects enrolled into
the study, and randomized into the QXD or placebo
arms. Three QXD treated patients dropped out at the
3, 4 and 7-week time points, and three placebo drop-
outs occurred at weeks 2, 5 and 6. Six dropouts gave
up the study due to private reasons, not for side effects
(Figure 3).
Ten subjects in each group completed the study. Base-
line subject characteristics are provided in Table 3, and
there were no significant differences between the two
groups.
1.00
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Figure 1 HPLC measurement of baicalin and berberine in
QXD
The 3.04% of baicalin and 3.95% of berberine are contained
in QXD, averagely. A: the amount of berberine in standard
Coptidis Rhizoma; B: the amount of berberine in QXD; C: the
amount of baicalin in standard Scutellariae Radix; D: The
amount of baicalin in QXD. HPLC: high performance liquid
chromatography; QXD: Qingxue Dan.
A
B
C
D
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Change of obesity
BMI in QXD group was significantly decreased during
the 8-week period (Table 4). After 8 week of treat-
ment, QXD group showed loss of TBF in DXA mea-
surement, but there was no significant difference. WC,
WHR, DXA ROI Fat mass was decreased in both
group, but there was no significant difference between
two groups (Table 5).
Change of blood pressure
The blood pressure in both groups was with in normal
range during the study period. There was no signifi-
cant change of blood pressure in each group during the
8 week of treatment period (Figure 4).
Change of lipid profile
In QXD group, TG was higher than placebo group
at baseline, but after treatment, it was further re-
duced than placebo group. LDL-c and HDL-c were
further increased in QXD group. TC was slightly in-
creased after treatment in both groups, but not signifi-
cant (Table 6).
Recruitment 31 Person were recruited
Screening Anthropometry, Historytaking, informed consent 5 screened out
Treatment
26 persons
Experimentalgroup
(13)
Control group (13)
1st visit
2nd-8th
visit
BIA, WC/HC, BP,
Side effect, diet and
exercise diary,
compliance survey
(every visit)
9th visit BIA, DXA, blood test
6 Dropped out
(6 for voluntary give up)
The end 20 SubjectsPlacebo group (10), QXD group (10)
Figure 3 Protocol and disposition of subjects enrolled in this study
QXD: Qingxue Dan; BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; WC: waist circumference; HC:
hip circumference; BP: blood pressure.
Table 3 Demographic characteristics ( xˉ ± s)
Item
Age (years)
Male/female (n)
Height (cm)
Body weight (kg)
BMI (kg/m2)
SBP (mm Hg)
DBP (mm Hg)
WC (cm)
HC (cm)
WHR
Placebo group (n=10)
45.20±9.52
6/4
167.17±9.56
80.96±11.16
28.89±2.96
125.50±10.66
84.00±11.74
97.59±3.79
104.31±4.66
0.94±0.04
QXD group (n=10)
50.00±5.85
6 /4
163.56±6.72
79.30±14.16
29.50±3.63
127.00±20.03
81.00±11.97
96.26±10.14
102.74±7.95
0.93±0.05
P valuea
0.244
0.123
0.335
0.283
0.368
0.825
0.483
0.432
0.710
Notes: the subjects in QXD group received 900 mg/day (three times a day, 300 mg at once) of encapsulated QXD extract, whereas the sub-
jects in the placebo group received 900 mg/day (three times a day, 300 mg at once) of encapsulated placebo medicine for 8 weeks. QXD:
Qingxue-dan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC: waist circumference; HC: hip cir-
cumference; WHR: waist-hip ratio. aP values are for Student's t-test.
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Change of insulin resistance
HOMA-IR values showed decreasing in both group
without significant group effect (Table 7).
Assessment of adverse event, and credibility
There were no adverse sign except burning sensation,
indigestion and fatigue for several volunteer, and no sig-
nificantly different between two groups (Table 8). Also
credibility between control group and experimental
group was not significantly different.
DISCUSSION
In the present study, BMI was decreased significantly
in QXD group. TBF, DXA ROI on abdominal fat
mass and WC showed a trend toward improvement in
the QXD group, but FFM were decreased in all group.
These findings may suggest that QXD treatment could
reduce caloric intake, but not have an influence on
physical activity. These findings are similar to a result
of prior study of QXD effects on high fat diet induced
Table 5 Anthropometric and body composition measured with DXA before and after 8-week of administration ( xˉ ± s)
Item
TBF (kg)
FFM (kg)
WC (cm)
WHR
ROI (kg)
Group
Placebo
QXD
Placebo
QXD
Placebo
QXD
Placebo
QXD
Placebo
QXD
n
10
10
10
10
10
10
10
10
10
10
Before
26.20±4.10
26.66±6.07
52.29±10.31
51.10±10.11
97.59±0.79
96.26±10.14
0.94±0.04
0.94±0.05
2.98±0.56
2.99±0.80
After
26.14±4.43
25.98±6.18
51.57±9.71
50.39±9.76
95.24±6.42
93.20±9.00
0.94±0.05
0.92±0.05
2.90±0.57
2.58±0.83
Change
－0.06±0.22
－0.68±0.60
－0.73±0.91
－0.71±1.39
－2.35±4.26
－3.06±4.39
0.01±0.03
－0.02±0.04
－0.08±0.26
－0.41±0.08
P valuea
>0.05
>0.05
>0.05
>0.05
>0.05
Notes: the subjects in QXD group received 900 mg/day of encapsulated QXD extract, whereas the subjects in the placebo group received
900 mg/day of encapsulated placebo for 8 weeks. QXD: Qingxue-dan; TBF: total body fat; FFM: fat free mass; WC: waist circumference;
WHR: waist hip ratio; ROI: range of interest for abdominal fat. aP value is for comparing changes of outcomes between two groups.
Group
Placebo
QXD
n
10
10
Before
28.9±3.0
29.5±3.6
After
28.2±2.5
28.8±3.4
Change
－0.69±0.83
－0.73±0.44
P valuea
0.044
Notes: the subjects in QXD group received 900 mg/d of encapsulated QXD extract, whereas the subjects in the placebo group received
900 mg/d of encapsulated placebo for 8 weeks. aP value is for comparing change of BMI between two groups. QXD: Qingxue-dan; BMI:
body mass index.
Table 4 Difference of BMI change after 8-week of administration ( xˉ ± s)
130
120
110
100
90
80
70
60
1 2 3 4 5 6 7 8 9 10
BP
(m
mH
g)
Placebo Systolic BP
Placebo Dystolic BP
QXD Systolic BP
QXD Dystolic BP
Figure 4 There was no significant change of blood pressure in each group during the 8 week of treatment period
QXD: Qingxue Dan; BP: blood pressure.
Week
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obesity and metabolic disorders.11 Also, it is known
that berberine, one of main ingredient in the QXD,
down-regulates activity of adipogenic enzymes and
transcription factors, and inhibits PPAR gamma and
alpha.15,16
Experimentally, QXD activates nitric oxide synthase
mRNA expression and suppresses vascular cell adhe-
sion molecule-1 mRNA expression in human endothe-
lial cells, suggesting that it has anti-atherogenic and an-
ti-hypertensive effects.17 In the present study, BP was
regulated in normal range from baseline to end of
study, and QXD didn't decrease BP forcibly. No signifi-
cant BP changes were observed between the QXD and
placebo groups. In a prior clinical study on BP-control-
ling effect, 2-weeks administration of QXD (1200 mg/
day) decreased systolic BP about 9 mm Hg in stroke
patients with essential hypertension.7 Some herbs such
as ginseng were reported that it could regulate BP bilat-
erally depending on dose,18 and QXD might have simi-
lar effect on blood pressure, but there is few dose-effect
study of QXD on BP.
In recent studies, QXD is known to have anti-hyperlip-
idemic activity, by inhibiting pancreatic lipase as well
as 3-hydroxy-3-methylglutaryl coenzyme A reductase.19
Further more, berberin does not only up-regulate the
LDL receptor, but also inhibit lipid synthesis in human
hepatocytes through the activation of AMP kinase and
decreased plasma LDL cholesterol, and strongly re-
duced fat storage in the liver.20-22 These effects could ex-
plain the reduction of plasma triglycerides observed in
Table 6 Change of lipid profiles ( xˉ ± s)
Item
TC (mg/dL)
TG (mg/dL)
LDL-c (mg/dL)
HDL-c (mg/dL)
Group
Placebo
QXD
Placebo
QXD
Placebo
QXD
Placebo
QXD
n
10
10
10
10
10
10
10
10
Normal
－200
50-150
－130
35-65
Before
191±47
194±39
144±67
206±64
124±42
131±41
50±15
40±4
After
191±44
203±50
144±74
185±68
126±41
136±43
52±15
43±9
Change
0±18
8±22
0±72
－21±60
2±18
6±16
2±6
3±6
P valuea
>0.05
0.001b
0.027c
0.016c
Notes: the subjects in QXD group received 900 mg/day of encapsulated QXD extract, whereas the subjects in the placebo group received
900 mg/day of encapsulated placebo for 8 weeks. QXD: Qingxue Dan; TC: total cholesterol; TG: triglyceride; LDL-c: low-density lipopro-
tein cholesterol; HDL-c: high-density lipoprotein cholesterol. aP value is for comparing changes of outcomes between two groups; bP <
0.01 as compared with the placebo group; cP < 0.05 as compared with the placebo group.
Table 7 Change of FBS, Insulin and HOMA-IR ( xˉ ± s)
Item
FBS (mg/dL)
Insulin (pg/mL)
HOMA-IR (units)
Group
Placebo
QXD
Placebo
QXD
Placebo
QXD
n
10
10
10
10
10
10
Before
108±15
117±38
855±604
544±196
226±160
164±93
After
100±16
119±48
911±1013
493±148
205±184
150±92
Change
－8±13
2±28
56±817
－50±252
－21±202
－14±94
P valuea
>0.05
>0.05
>0.05
Notes: the subjects in QXD group received 900 mg/day of encapsulated QXD extract, whereas the subjects in the placebo group received
900 mg/day of encapsulated placebo for 8 weeks. QXD: Qingxue Dan; FBS: fasting blood sugar; HOMA-IR: homeostasis model assess-
ment for insulin resistance. aP value is for comparing of changing outcomes between two groups.
Table 8 Adverse event and credibility [n (%)]
Adverse Event
Credibility
Item
No
Yes
Control group
Experiment group
Unknown
Placebo (n=10)
10 (100.0)
0 (0.0)
5 (50.0)
1 (10.0)
4 (40.0)
QXD (n=10)
7 (70.0)
3 (30.0)
3 (30.0)
5 (50.0)
2 (20.0)
P valuea
0.211
0.246
Notes: the subjects in QXD group received 900 mg/day of encapsulated QXD extract, whereas the subjects in the placebo group received
900 mg/day of encapsulated placebo for 8 weeks. QXD: Qingxue Dan. a: P value is for Fisher's exact test.
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this clinical trial. In lipid profiles, TG was decreased
significantly after treatment even though initial value
was higher than placebo group. And cholesterol, LDL
and HDL were increased in QXD group. In a previous
clinical study on hypercholesterolemia patients, QXD
(600 mg/day) showed significant lipid-lowering effects
especially on TC and LDL-c, but not on TG and
HDL-c.6 In another study shown effect of QXD on hy-
perlipidemia, level of TG also improved.23 It is possible
that change of each lipid profiles is due to lifestyle such
as alcohol consumption and dietary variations, and we
couldn't control that variation strictly in this study.
There is few evidence of QXD on anti-hyperglycemic
effects, but berberine improved glucose metabolism
both in blood and liver in diabetic rats possibly
through modulating the metabolic related PPAR alpha/
delta/gamma protein expression in liver,24 and increases
glucose uptake through a mechanism distinct from in-
sulin.25 Also, long term administration of baicalin, one
of major ingredient in QXD, decreased elevated serum
insulin and glucose in high-fat diet-fed rats.26 In the
present study, insulin sensitivity assessed with
HOMA-IR showed a trend toward decrease in the pla-
cebo and QXD group. It is possible that life style relat-
ed factors (diet, physical activity, etc.) could affect insu-
lin sensitivity, and more research is needed to deter-
mine the effect of QXD on glucose metabolism.
This study has several limitations. Calorie intake and
exercise are assumed beforehand, but there were indi-
vidual differences. Also small scale and 6 withdraw are
difficult to statistical validity, and make these findings
preliminary. Considering this study, large scale and
more precise study in combination with detailed assess-
ment of life-style related factors would be needed.
In conclusion, 8-weeks oral administrations of QXD
(900 mg/d) results in reduction of BMI, with a
tendency of lose of body fat mass, especially abdominal
fat. It also significantly reduced serum TG level. These
results suggest QXD could be used to treat obesity and
metabolic risk factors. Further study is needed to
confirm our pilot findings.
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